SCHEMBL7713283

SCHEMBL7713283

CC1Oc2ccc(C(Cc3cccc([N+](=O)[O-])c3)NC(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.39
NR3C2 P08235 1/20 0.38
MAPT P10636 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALOX5 P09917 1/20 0.37
NPC1 O15118 1/20 0.37
CCKAR P32238 1/20 0.35
CCKBR P32239 1/20 0.35
IDO1 P14902 1/20 0.35
ITGA4 P13612 1/20 0.35
ITGB7 P26010 1/20 0.35
HTT P42858 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMYD3 Q9H7B4 1/20 0.34
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7095517 0.91 SIRT2 (0.38) SIRT2NR3C2MAPTRAB9ASMN1; SMN2
SCHEMBL7711091 0.89 PARP1 (0.42) PARP1SMN1; SMN2CCKARCCKBRIDO1
SCHEMBL7713374 0.87 PARP1 (0.50) PARP1MAPTRAB9ASMN1; SMN2CCKAR
SCHEMBL7713251 0.87 CTSS (0.45) PARP1SMN1; SMN2CCKARCCKBRIDO1
SCHEMBL7711137 0.87 CTSL (0.45) PARP1SMN1; SMN2CCKARCCKBRIDO1
SCHEMBL7708231 0.86 CA2 (0.39) PARP1ITGA4ITGB7
SCHEMBL7708220 0.85 PARP1 (0.41) PARP1CCKARCCKBRIDO1HTT
SCHEMBL7711371 0.83 PARP1 (0.41) PARP1MAPTRAB9ASMN1; SMN2CCKAR
SCHEMBL7713294 0.83 PARP1 (0.42) PARP1SMN1; SMN2CCKARCCKBRIDO1
SCHEMBL7713423 0.83 PARP1 (0.41) PARP1SMN1; SMN2CCKARCCKBRIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed